Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

aspirin

aspirin
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Durlaza CAPSULE, EXTENDED RELEASE, ORAL 162.5 mg    
Vazalore CAPSULE, ORAL 81 mg, 325 mg    
Aspirin DELAYED RELEASE TABLET, ORAL 81 mg, 325 mg (Enteric)      
Aspirin SUPPOSITORY, RECTAL 300 mg, 600 mg      
Aspirin TABLET, CHEWABLE, ORAL 81 mg      
Aspirin TABLET, DISINTEGRATING, ORAL 81 mg    
Aspirin TABLET, ORAL buffered 325 mg      
Aspirin TABLET, ORAL 325 mg      
VIEW MORE Salicylates, Replacement Preparations
CLASS
28080424, 401200
Comments:

Vazalore is approved for sample use in HH Endocrinology and Diabetes Clinics.

Tip sheet for Aspirin Desensitization

Fasprin (aspirin 81 mg ODT) and Fasprin Women's Heart Health Formula are designated as non-formulary, not stocked. Interchange to the formulary aspirin 81 mg product.

Vazalore (liquid capsule) should be automatically interchanged to an immediate-release or enteric coated aspirin product on a 1 mg:1 mg ratio at the same dosing interval.

 

ORDERED FORMULATION

FORMULARY INTERCHANGE

aspirin controlled release (Durlaza)

  • 162.5 mg

 aspirin EC

  • 81 mg

 

 

Reviewed: February 26, 2008 (FASPRIN), 26 January 2016 (DURLAZA), March 2022 (VAZALORE)

 

Last updated: Jan. 17, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved